CTLA4 and cancer: In recent years the introduction of checkpoint inhibitor immunotherapy drugs that block proteins suppressing T cell responses as Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed death-ligand 1 (PD-1) and its ligand PD-L1 have radically changed the treatment approach and prognosis of many cancers.